Notable, combination aromatase inhibitor plus COX-2 inhibitor therapy has shown a synergistic antitumor effect in several preclinical studies, including lung cancer, and was evaluated in several clinical trials [42–44]. Here, PTGS2 is linked to lung carcinoma.